Pazopanib, a promising option for the treatment of aggressive fibromatosis.

abstract：:Esophageal cancer is one of the fatal cancers around the world. Dexmedetomidine (DEX) is widely used during anesthesia of esophageal cancer surgery. Nevertheless, the role of DEX in the progression of esophageal cancer remains barely known. The proliferation, apoptosis and metastasis of esophageal cancer cells were de...

journal_title：Anti-cancer drugs

authors： Zhang P,He H,Bai Y,Liu W,Huang L

更新日期：2020-08-01 00:00:00

abstract：:Small molecule tyrosine kinase inhibitors are rapidly being integrated into the management of cancer. This is the first report of sorafenib and sunitinib, both small molecule tyrosine kinase inhibitors of vascular endothelial growth factor and platelet-derived growth factor receptors, triggering radiation recall derma...

journal_title：Anti-cancer drugs

authors： Chung C,Dawson LA,Joshua AM,Brade AM

更新日期：2010-02-01 00:00:00

abstract：:PC cell-derived growth factor is a novel growth factor for tumor formation and progression. No comprehensive literature concerning PC cell-derived growth factor expression status and its biological function in squamous cell carcinoma, especially in the larynx, is, however, available. The target of this study is to eva...

journal_title：Anti-cancer drugs

authors： Kong WJ,Zhang SL,Chen X,Zhang S,Wang YJ,Zhang D,Sun Y

更新日期：2007-01-01 00:00:00

abstract：:The aim of this study was to evaluate whether radiolabeled iodoerythronitroimidazole (IETNIM) could predict the radiosensitization effect on tumors. Tumor-bearing mice were irradiated at a dose of 25, 31 and 37 Gy after the injection of IETNIM. They were also exposed to 37 Gy radiation at 35, 70, 140 and 240 min after...

journal_title：Anti-cancer drugs

authors： Inoue T,Yang DJ,Wallace S,Cherif A,Tansey W,Kim EE,Hunter N,Milross CG,Milas L,Podoloff DA

更新日期：1996-11-01 00:00:00

abstract：:Colchicine, the main alkaloid of the poisonous plant meadow saffron (Colchicum autumnale L.), is a classical drug used for the treatment of gout and familial Mediterranean fever. Although colchicine is not clinically used to treat cancer because of toxicity, it exerts antiproliferative effects through the inhibition o...

journal_title：Anti-cancer drugs

authors： Kumar A,Sharma PR,Mondhe DM

更新日期：2017-03-01 00:00:00

abstract：:A combined treatment with conventional chemotherapies can enhance the effectiveness of chemotherapeutic agents against cancers. Here, we have shown that the naturally occurring triterpenoids synergistically enhance the response of cervical cancer cells to taxol. Of the triterpenoid compounds, pristimerin enhanced the ...

journal_title：Anti-cancer drugs

authors： Eum DY,Byun JY,Yoon CH,Seo WD,Park KH,Lee JH,Chung HY,An S,Suh Y,Kim MJ,Lee SJ

更新日期：2011-09-01 00:00:00

abstract：:Transcatheter arterial chemoembolization (TACE) is widely used to treat unresectable hepatocellular carcinoma (HCC). Recently, a fine-powder formulation of cisplatin (DDP-H) was developed in Japan. We aimed to compare clinical outcomes after TACE using epirubicin or DDP-H in patients with HCC. We evaluated 202 patient...

journal_title：Anti-cancer drugs

authors： Yodono H,Matsuo K,Shinohara A

更新日期：2011-03-01 00:00:00

abstract：:Venetoclax is a first-in-class orally available, B-cell lymphoma (BCL)-2 inhibitor indicated for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. We used a novel approach for evaluating venetoclax pharmacokinetics using only sparse sampling in 155 patien...

journal_title：Anti-cancer drugs

authors： Salem AH,Dunbar M,Agarwal SK

更新日期：2017-09-01 00:00:00

abstract：:A lack of cross-resistance between the aromatase inhibitors (AIs) provides evidence to suggest that there are clinical differences between these agents. Available data from clinical trials indicate that patients exposed to nonsteroidal AIs may benefit from a steroidal compound of similar biochemical potency, and durab...

journal_title：Anti-cancer drugs

authors： Lønning PE

更新日期：2008-03-01 00:00:00

abstract：:This phase I study was performed to assess the feasibility of combining cisplatin/etoposide (VP-16) with the arotinoid Ro 40-8757 and to determine the dose-limiting toxicity (DLT) of Ro 40-8757 in this combination. Patients with non-small cell lung cancer were eligible. Treatment consisted of Ro 40-8757 p.o. day 1-21,...

journal_title：Anti-cancer drugs

authors： van Zuylen L,Schellens JH,Goey SH,Pronk LC,de Boer-Dennert MM,Loos WJ,Ma J,Stoter G,Verweij J

更新日期：1999-04-01 00:00:00

abstract：:Acquired docetaxel (Doc) resistance in hormone-refractory prostate cancer (HRPC) remains an ongoing clinical challenge, resulting in failed chemotherapy and tumor recurrence. However, the mechanism of Doc-resistance development in prostate cancer cells is still unclear. Here, we observed a subpopulation of prostate ca...

journal_title：Anti-cancer drugs

authors： Qiu S,Deng L,Bao Y,Jin K,Tu X,Li J,Liao X,Liu Z,Yang L,Wei Q

更新日期：2018-10-01 00:00:00

abstract：:Caffeic acid phenethyl ester (CAPE) is a major propolis component that possesses a variety of pharmacological properties such as antioxidant and anticancer effects. Herein, we investigated the effectiveness of CAPE on cytotoxicity of clinically used anticancer drugs, doxorubicin (DXR) and cisplatin (CDDP), in parental...

journal_title：Anti-cancer drugs

authors： Matsunaga T,Tsuchimura S,Azuma N,Endo S,Ichihara K,Ikari A

更新日期：2019-03-01 00:00:00

abstract：:We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer. Medical care consumption data were collected prospective...

journal_title：Anti-cancer drugs

authors： Schmitt C,Blijham G,Jolain B,Rougier P,Van Cutsem E

更新日期：1999-07-01 00:00:00

abstract：:In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetin...

journal_title：Anti-cancer drugs

authors： Boers-Sonderen MJ,Desar IM,Blokx W,Timmer-Bonte JN,van Herpen CM

更新日期：2012-08-01 00:00:00

abstract：:Schlafen-11 (SLFN11) showed a highly significant positive correlation with the response of topoisomerase inhibitors in cancer cell lines derived from prostate, lung, etc. However, this finding has not been validated in colorectal cancers (CRCs). Although irinotecan (CPT-11), a topoisomerase inhibitor, is one of the mo...

journal_title：Anti-cancer drugs

authors： Tian L,Song S,Liu X,Wang Y,Xu X,Hu Y,Xu J

更新日期：2014-11-01 00:00:00

abstract：:Urothelial carcinoma of the bladder accounts for over 95% of bladder tumours in France. The incidence of this disease is increasing in industrialised countries. Several types of bladder cancer can be distinguished: (1) superficial tumours which have a risk of recurrence and progression, although conservative treatment...

journal_title：Anti-cancer drugs

authors： Rischmann P

更新日期：2000-10-01 00:00:00

abstract：:The tolerance to adriamycin of cancer as a common and stubborn obstacle occurred during curing breast cancer patients needs to be overcome. In the present study, we explored whether inhibiting the glucose transporter 1 (GLUT1) could restore the activity of adriamycin in breast cancer cell line MCF-7 resistant to adria...

journal_title：Anti-cancer drugs

authors： Chen Q,Meng YQ,Xu XF,Gu J

更新日期：2017-09-01 00:00:00

abstract：:Different derivatives of nitrosoureas were synthesized by a long sequence of reactions and were evaluated for their anticancer activities against female Swiss albino mice, 6-8 weeks old, weighing 18-24 g and bearing Sarcoma-180 (S-180) ascitic tumor. Experimental protocols include injecting a total of 2 x 10(5) S-180 ...

journal_title：Anti-cancer drugs

authors： Nyati MK,Rajoria CM,Gupta RR,Dev PK

更新日期：1995-10-01 00:00:00

abstract：:Since their addition to paclitaxel in the oncologists' armamentarium in the early 1990s, several new taxane formulations have been developed. Besides docetaxel and nab-paclitaxel, new analogs with better therapeutic profiles are being investigated. The goals of this next generation of taxanes are to improve the toxici...

journal_title：Anti-cancer drugs

authors： Muggia F,Kudlowitz D

更新日期：2014-05-01 00:00:00

abstract：:We demonstrate that neurokinin A (NKA) and substance P (SP) play a role in the proliferation of the estrogen receptor-negative (ER-) cell line MDA-MB-231, a human breast carcinoma expressing both NK-1 and NK-2 receptors. In vitro experiments showed that the specific receptor antagonists MEN 11,467 (NK-1) and nepadutan...

journal_title：Anti-cancer drugs

authors： Bigioni M,Benzo A,Irrissuto C,Maggi CA,Goso C

更新日期：2005-11-01 00:00:00

abstract：:Advanced stage neuroblastoma is a very aggressive pediatric cancer with limited treatment options and a high mortality rate. Glycogen synthase kinase-3β (GSK-3β) is a potential therapeutic target in neuroblastoma. Using immunohistochemical staining, we observed positive GSK-3β expression in 67% of human neuroblastomas...

journal_title：Anti-cancer drugs

authors： Ugolkov AV,Bondarenko GI,Dubrovskyi O,Berbegall AP,Navarro S,Noguera R,O'Halloran TV,Hendrix MJ,Giles FJ,Mazar AP

更新日期：2018-09-01 00:00:00

abstract：:It is crucial to incorporate new and more potent antineoplastic agents in treating non-Hodgkin's lymphoma since standard chemotherapy fails to cause a significant increase in the survival rate. A potential chemotherapeutic agent is dolastatin 10; hence, the objective of our study is to investigate the effect of the an...

journal_title：Anti-cancer drugs

authors： Maki A,Mohammad R,Raza S,Saleh M,Govindaraju KD,Pettit GR,al-Katib A

更新日期：1996-05-01 00:00:00

abstract：:The antitumor effects of a polyamine biosynthetic pathway inhibitor methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP) on the human hepatocellular carcinoma SK-HEP-1 cell line have been investigated. The growth of these cultured hepatocellular carcinoma cells was inhibited by MGBCP in a dose-dependent manner. Sper...

journal_title：Anti-cancer drugs

authors： Hashimoto Y,Hibasami H,Tamaki S,Kamei A,Ikoma J,Kaito M,Imoto I,Watanabe S,Nakashima K,Adachi Y

更新日期：1999-03-01 00:00:00

abstract：:1,4-Anthraquinone (AQ) was synthesized and shown to prevent L1210 leukemic cells from synthesizing macromolecules and growing in vitro. In contrast, its dihydroxy-9,10anthraquinone precursor, quinizarin, was inactive. The antitumor activity of AQ was compared to that of daunorubicin (DAU), which is structurally differ...

journal_title：Anti-cancer drugs

authors： Perchellet EM,Magill MJ,Huang X,Dalke DM,Hua DH,Perchellet JP

更新日期：2000-06-01 00:00:00

abstract：:High expression of vascular endothelial growth factor (VEGF) in patients with breast cancer has been associated with a poor prognosis, indicating that VEGF could be linked to the efficacy of chemotherapy and radiotherapy. It has also been suggested that radiation resistance is partly due to tumour cell production of a...

journal_title：Anti-cancer drugs

authors： Heravi M,Tomic N,Liang L,Devic S,Holmes J,Deblois F,Radzioch D,Muanza T

更新日期：2012-06-01 00:00:00

abstract：:Interleukin-12 (IL-12) has important immunomodulatory effects on T and natural killer (NK) cells that might be exploited in anticancer treatment. Murine IL-12 models have shown antimetastatic and antitumor effects against murine tumors in vivo. Data on the effects of human IL-12 on human tumors are confined to 51Cr-re...

journal_title：Anti-cancer drugs

authors： Izquierdo MA,Degen D,Sypek JP,Von Hoff DD

更新日期：1996-05-01 00:00:00

abstract：:This study aims to investigate the significance and mechanism of artesunate involved in suppressing the proliferation of gastric cancer in vitro and in vivo. In the in-vitro experiments, artesunate inhibited the growth of gastric cancer cell lines (SGC-7901, BGC-823, and AGS) with concentration-dependent activity, wit...

journal_title：Anti-cancer drugs

authors： Zhou X,Sun WJ,Wang WM,Chen K,Zheng JH,Lu MD,Li PH,Zheng ZQ

更新日期：2013-10-01 00:00:00

abstract：:There is limited evidence on the costs associated with ipilimumab. We investigated healthcare costs of all Dutch patients with advanced cutaneous melanoma who were treated with ipilimumab. Data were retrieved from the nation-wide Dutch Melanoma Treatment Registry. Costs were determined by applying unit costs to indivi...

journal_title：Anti-cancer drugs

authors： Franken MG,Leeneman B,Jochems A,Schouwenburg MG,Aarts MJB,van Akkooi ACJ,van den Berkmortel FWPJ,van den Eertwegh AJM,de Groot JWB,van der Hoeven KJM,Hospers GAP,Kapiteijn E,Koornstra R,Kruit WHJ,Louwman MWJ,Piersma D,van

更新日期：2018-07-01 00:00:00

abstract：:A patient with platinum resistant low-grade serous ovarian carcinoma had an objective response to therapy with bevacizumab and evidence of extended activity (>7 years). This case report adds to the growing literature regarding the use of bevacizumab in low-grade serous ovarian carcinoma. ...

journal_title：Anti-cancer drugs

authors： Rose PG,Roma A

更新日期：2013-10-01 00:00:00

abstract：:Glucocorticosteroids (GC) play an important role in the treatment of neuro-oncologic patients. GC are used for the management of malignant brain tumors, either primary of secondary, neoplastic epidural spinal cord compression (NESC), as adjuvant chemotherapy of some central nervous system tumors and perioperatively in...

journal_title：Anti-cancer drugs

authors： Koehler PJ

更新日期：1995-02-01 00:00:00